Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free
分子别名（Synonym）
DDPAC,FTDP-17,MAPT,MSTD,MTBT1,Tau,PHF-tau,TAU
表达区间及表达系统（Source）
Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free (TAU-H5113) is expressed from E. coli cells. It contains AA Gln 244 - Glu 372 (Accession # P10636-8 (P301L)).
Predicted N-terminus: Met
蛋白结构（Molecular Characterization）
This protein carries no "tag".
The protein has a calculated MW of 13.8 kDa.
应用说明（Application）
THT, cell assay, drug screening and other in vitro experiment.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Supplied as 0.2 μm filtered solution in PBS, pH7.4.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product should be stored at -70°C or room temperature for short storage. Do not store fibrils on ice or at 4°C;
The unsonicated fibril is validated to be stable after storage at -70°C for 1 year under sterile conditions;
The sonicated fibril should be stored at -70°C for not more than 8 weeks.
背景（Background）
Tau is a microtubule-associated protein, which encodes by the MAPT gene that located on chromosome 17q21. Tau Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. Hyperphosphorylation of the tau protein (tau inclusions, pTau) can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease, frontotemporal dementia, and other tauopathies. Tau-441 is known as "2N4R," "Isoform Tau-F," "Tau-4" or "Tau 441", which consisting of 441 amino acid. Tau-441 is a potential therapeutic target for pathogenesis.
关键字： Tau441;Tau441蛋白;Tau441重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。